Erythropoietin biosimilar - Incepta Pharmaceuticals
Alternative Names: Epoetin - Incepta Pharmaceuticals; Erythropoietin 2000 IU - Incepta Pharmaceuticals; Erythropoietin 3000 IU - Incepta Pharmaceuticals; Erythropoietin 4000 IU - Incepta Pharmaceuticals; Erythropoietin 5000 IU - Incepta Pharmaceuticals; Erythropoietin alfa biosimilar - Incepta PharmaceuticalsLatest Information Update: 04 Jul 2025
At a glance
- Originator Incepta Pharmaceuticals
- Class Antianaemics; Erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Anaemia
Most Recent Events
- 24 Apr 2025 Phase-III clinical trials in Anaemia (In volunteers) in Bangladesh (SC) (NCT07025681)